Shortened Tacrolimus + Post-transplantation Cyclophosphamide Regimen

This entry refers to a specific clinical protocol developed by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins for patients undergoing nonmyeloablative, related donor bone marrow transplantation (BMT). The regimen focuses on graft-versus-host disease (GVHD) prophylaxis using high-dose post-transplantation cyclophosphamide (PTCy) followed by a shortened duration of tacrolimus prophylaxis (tapered to stop at 60, 90, or 120 days) and mycophenolate mofetil. This approach, often referred to as a 'mini-transplant,' aims to reduce the long-term toxicity and infectious risks associated with extended immunosuppression while maintaining the low rates of GVHD and effective graft-versus-tumor effects typically observed with the Johns Hopkins PTCy platform.

Other names

Shortened Tacrolimus Duration in Haplo-BMTPTCy with shortened tacrolimusJohns Hopkins BMT protocol